Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma

Brief summary (registry, in English)

This is a randomized, double-blind, placebo-controlled, multicenter Phase 3 study to evaluate the efficacy and safety of ibrutinib in combination with rituximab versus placebo in combination with rituximab in treatment naïve participants with follicular lymphoma (FL).

What you commit to

• Study type: Interventional · Phase 3
• Participants enrolled: 445
• From 23 Jan 2017 to the primary completion date, 21 Feb 2024
• 123 sites in 19 countries
• Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Who the study is looking for

Age in the registry: 60 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (123)

Sites in registry order. Pick your city on the disease page to sort them by distance.